Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ALK Abello reports positive trial data for ragweed allergy treatment

ALK Abello reports positive trial data for ragweed allergy treatment

8th August 2011

ALK Abello has published positive data from two clinical trials of its new treatment for ragweed allergy.

The company has completed a pair of pivotal phase III studies of the investigational sublingual Ragweed Allergy Immunotherapy Tablet, conducted among around 1,350 patients in conjunction with Merck Sharpe and Dohme.

It was found that the drug was able to reduce allergy symptoms and use of concomitant symptom-relieving medication, thus meeting its combined primary efficacy endpoint.

It was also shown to be well tolerated by patients, with no new or unexpected findings regarding adverse events.

Jens Bager, president and chief executive officer of ALK Abello, said: "We are very excited by the successful outcome of these important studies in the first large programme with a sublingual ragweed immunotherapy tablet."

Last month, the company announced a new alliance with AllerQuest that will focus on the development and sale of a penicillin diagnostic product.ADNFCR-8000103-ID-800692263-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.